LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $97.60 Average Target Price from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $97.60.

Several equities analysts have recently weighed in on LMAT shares. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a report on Wednesday, August 6th. Cantor Fitzgerald raised their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th.

Insiders Place Their Bets

In related news, Director John A. Roush sold 6,561 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock worth $11,280,206 in the last quarter. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LMAT. Parkside Financial Bank & Trust grew its position in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 287 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $26,000. NBC Securities Inc. acquired a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $36,000. Geneos Wealth Management Inc. grew its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $47,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Down 2.1%

NASDAQ:LMAT opened at $92.29 on Wednesday. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The business has a 50 day moving average price of $89.69 and a two-hundred day moving average price of $86.06. The company has a market cap of $2.09 billion, a P/E ratio of 44.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the prior year, the firm posted $0.52 EPS. The business’s revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular’s dividend payout ratio is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.